目次

TABLE OF CONTENT

1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 KEY INCLUSIONS & EXCLUSIONS
1.3 RESEARCH SCOPE
1.3.1 SEGMENTS COVERED
1.3.2 GEOGRAPHIC SCOPE
1.3.3 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY USED FOR THE STUDY
1.5 MAJOR MARKET STAKEHOLDERS
1.6 RECESSION IMPACT

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA SOURCES
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET SIZE ESTIMATION METHODOLOGY
2.3 MARKET SHARE ESTIMATION METHODOLOGY
2.4 MARKET BREAK DOWN AND DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.6.1 SCOPE RELATED LIMITATIONS
2.6.2 METHODOLOGY RELATED LIMITATIONS
2.7 RISK ASSESSMENT
2.8 RECESSION IMPACT ASSESSMENT APPROACH

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 MARKET OVERVIEW
5.1 MARKET DYNAMICS
5.1.1 MAJOR DRIVERS
5.1.2 KEY RESTRAINTS
5.1.3 KEY GROWTH OPPORTUNITIES
5.1.4 INDUSTRY-SPECIFIC CHALLENGES
5.2 REGULATORY LANDSCAPE
5.2.1 REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS
5.2.2 REGULATORY ANALYSIS
5.3 VALUE CHAIN ANALYSIS
5.4 SUPPLY CHAIN ANALYSIS
5.5 ECOSYSTEM MARKET MAP
5.6 TECHNOLOGY ANALYSIS
5.7 TRADE DATA ANALYSIS
5.8 PATENT ANALYSIS
5.9 PORTER’S FIVE FORCE ANALYSIS
5.10 PRICING ANALYSIS
5.10.1 AVERAGE SELLING PRICE OF KEY PLAYERS BY PRODUCT
5.10.2 AVERAGE SELLING PRICE TRENDS
5.11 KEY CONFERENCES AND EVENTS IN 2022-23
5.12 KEY STAKEHOLDERS AND BUYING CRITERIA
5.12.1 KEY STAKEHOLDERS AND BUYING CRITERIA
5.12.2 BUYING CRITERIA

6 MICROCATHETERS MARKET, BY PRODUCT TYPE (USD MILLION; 2021—2028)*
6.1 DELIVERY MICROCATHETERS
6.2 ASPIRATION MICROCATHETERS
6.3 DIAGNOSTIC MICROCATHETERS
6.4 STEERABLE MICROCATHETERS

7 MICROCATHETERS MARKET, BY APPLICATION (USD MILLION; 2021—2028)*
7.1 CARDIOVASCULAR APPLICATIONS
7.2 NEUROVASCULAR APPLICATIONS
7.3 PERIPHERAL VASCULAR APPLICATIONS G
7.4 ONCOLOGY APPLICATIONS

8 MICROCATHETERS MARKET, BY END-USER (USD MILLION; 2021—2028)*
8.1 HOSPITALS, SURGICAL CENTERS, AND SPECIALTY CLINICS
8.2 AMBULATORY CARE CENTERS
8.3 OTHER END-USERS

9 MICROCATHETERS MARKET, BY REGION (USD MILLION; 2021—2028)*
9.1 NORTH AMERICA
9.1.1 US
9.1.2 CANADA
9.2 EUROPE
9.2.1 GERMANY
9.2.2 UK
9.2.3 FRANCE
9.2.4 ITALY
9.2.5 SPAIN
9.2.6 REST OF EUROPE
9.3 ASIA-PACIFIC
9.3.1 JAPAN
9.3.2 CHINA
9.3.3 INDIA
9.3.4 SOUTH KOREA
9.3.5 AUSTRALIA
9.3.6 REST OF ASIA-PACIFIC
9.4 LATIN AMERICA
9.4.1 BRAZIL
9.4.2 MEXICO
9.4.3 REST OF LATIN AMERICA
9.5 MIDDLE EAST AND AFRICA

10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 REVENUE SHARE ANALYSIS OF KEY PLAYERS (2022)
10.3 MARKET SHARE ANALYSIS FOR TOP 3 - 5 GLOBAL PLAYERS (IN TERMS OF %REVENUE, IN 2022)
10.4 COMPANY FOOTPRINT ANALYSIS
10.5 COMPETITIVE BENCHMARKING
10.6 COMPETITIVE SITUATION AND TRENDS (2021-2023)
10.6.1 PRODUCT LAUNCHES AND APPROVALS
10.6.2 DEALS
10.7 COMPANY EVALUATION QUADRANT
10.7.1 PERVASIVE PLAYERS
10.7.2 EMERGING LEADERS
10.7.3 PARTICIPANTS
10.7.4 STARS
10.8 SME/START-UP EVALUATION QUADRANT
10.8.1 PROGRESSIVE COMPANIES
10.8.2 RESPONSIVE COMPANIES
10.8.3 DYNAMIC COMPANIES
10.8.4 STARTING BLOCKS

11 COMPANY PROFILES**
(Business Overview, Products Offered, Industry-specific Developments for 2021-2023)***
11.1 MAJOR PLAYERS
11.1.1 BOSTON SCIENTIFIC CORPORATION
11.1.2 ASAHI INTECH CO LTD
11.1.3 MEDTRONIC PLC
11.1.4 STRYKER CORPORATION
11.1.5 BECTON DICKINSON AND COMPANY
11.1.6 TERUMO MEDICAL CORPORATION
11.1.7 MERIT MEDICAL SYSTEMS
11.1.8 CARDINAL HEALTH
11.1.9 B. BRAUN MELSUNGEN
11.1.10 COOK MEDICAL
11.1.11 TELEFLEX
11.1.12 JOHNSON & JOHNSON
11.1.13 ANGIODYNAMICS
11.1.14 PENUMBRA
11.1.15 BTG PLC
11.2 OTHER PLAYERS
11.2.1 GUERBET LLC
11.2.2 EMBOLX INC
11.2.3 TOKAI MEDICAL
11.2.4 KANEKA CORPORATION
11.2.5 INTEGER HOLDINGS CORPORATION
11.2.6 LIBATAPE PHARMACEUTICAL CO LTD
11.2.7 REFLOW MEDICAL
11.2.8 SPARTAN MICRO
11.2.9 TRANSIT SCIENTIFIC
11.2.10 TRISALUS LIFE SCIENCES

12 APPENDIX
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 AVAILABLE CUSTOMIZATIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS